CRBU250516C1000
- 0.05
- 0.000.00%
Caribou Biosciences Newsroom
H.C. Wainwright Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Cuts Target Price to $3
Caribou Biosciences Analyst Ratings
HC Wainwright & Co. Maintains Buy on Caribou Biosciences, Lowers Price Target to $3
Truist Financial Maintains Caribou Biosciences(CRBU.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Caribou Biosciences (CRBU), Olema Pharmaceuticals (OLMA) and Privia Health Group (PRVA)
Truist Removes Price Target on Caribou Biosciences, Keeps Buy Rating; Price Target Was $19
Caribou Biosciences Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Caribou Biosciences, Maintains $9 Price Target
Analysts Remain Bullish on Caribou Biosciences (CRBU) Despite Ongoing Slump in Its Shares
Evercore Maintains Caribou Biosciences(CRBU.US) With Hold Rating, Maintains Target Price $3
Evercore ISI Sticks to Their Hold Rating for Caribou Biosciences (CRBU)
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH), Caribou Biosciences (CRBU) and CervoMed (CRVO)
BofA Securities Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $11
BofA Securities Cuts Price Target on Caribou Biosciences to $11 From $13, Maintains Buy Rating
Caribou Biosciences Analyst Ratings
Citi Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Cuts Target Price to $6
H.C. Wainwright Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $9
HC Wainwright & Co. Reiterates Buy on Caribou Biosciences, Maintains $9 Price Target
Caribou Biosciences' Strategic Advancements and Financial Efficiency Bolster Buy Rating
Evercore Maintains Caribou Biosciences(CRBU.US) With Hold Rating, Maintains Target Price $3